Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


25.02.2019

1 Arch Pathol Lab Med
1 Biochem Pharmacol
1 BJU Int
8 Clin Genitourin Cancer
1 Epidemiology
2 Eur Rev Med Pharmacol Sci
1 Eur Urol
1 Eur Urol Focus
1 Expert Rev Proteomics
1 Int Braz J Urol
3 J Cell Physiol
2 J Exp Clin Cancer Res
1 J Gastrointest Oncol
1 J Med Chem
1 J Urol
1 Med Sci Monit
1 Mol Cancer Ther
1 Neoplasma
1 Oncogene
1 Oncotarget
1 PLoS One
1 Proc Natl Acad Sci U S A
1 Prog Urol
2 Scand J Urol
1 Urol Ann
2 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Arch Pathol Lab Med

  1. MIRSADRAEI L, Hodkoff A, Jones K, Shabaik A, et al
    Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
    Arch Pathol Lab Med. 2018;142:168-177.
    PubMed     Text format     Abstract available


    Biochem Pharmacol

  2. ZHANG G, Ma F, Li L, Li J, et al
    Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex.
    Biochem Pharmacol. 2019;163:133-141.
    PubMed     Text format     Abstract available


    BJU Int

  3. BRASSETTI A, Moller A, Laurin O, Hoijer J, et al
    Evolution of cystectomy care over an 11-year period in a high-volume tertiary referral centre.
    BJU Int. 2018;121:752-757.
    PubMed     Text format     Abstract available


    Clin Genitourin Cancer

  4. POWLES T, Necchi A, Rosen G, Hariharan S, et al
    Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
    Clin Genitourin Cancer. 2018;16:117-129.
    PubMed     Text format     Abstract available

  5. LORENTZ CA, Gilbert K, Alemozaffar M, Patil D, et al
    Risk of Readmission After Uncomplicated Hospitalization After Radical Cystectomy.
    Clin Genitourin Cancer. 2018;16:e705-e710.
    PubMed     Text format     Abstract available

  6. GUPTA S, Albertson D, Gaston D, Heilbrun ME, et al
    Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System.
    Clin Genitourin Cancer. 2018;16:e373-e382.
    PubMed     Text format     Abstract available

  7. BREYER J, Wirtz RM, Erben P, Worst TS, et al
    High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
    Clin Genitourin Cancer. 2018;16:248-256.
    PubMed     Text format     Abstract available

  8. SONPAVDE G, Pond GR, Rosenberg JE, Choueiri TK, et al
    Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.
    Clin Genitourin Cancer. 2018;16:e961-e967.
    PubMed     Text format     Abstract available

  9. HENSLEY PJ, Goodwin J, Davenport DL, Strup SE, et al
    Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
    Clin Genitourin Cancer. 2018;16:e851-e858.
    PubMed     Text format     Abstract available

  10. MENG X, Press B, Renson A, Wysock JS, et al
    Discriminative Ability of Commonly Used Indexes to Predict Adverse Outcomes After Radical Cystectomy: Comparison of Demographic Data, American Society of Anesthesiologists, Modified Charlson Comorbidity Index, and Modified Frailty Index.
    Clin Genitourin Cancer. 2018;16:e843-e850.
    PubMed     Text format     Abstract available

  11. LIU ST, Hui G, Mathis C, Chamie K, et al
    The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Clin Genitourin Cancer. 2018;16:e269-e276.
    PubMed     Text format     Abstract available


    Epidemiology

  12. MARGULIS AV, Fortuny J, Kaye JA, Calingaert B, et al
    Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom.
    Epidemiology. 2018;29:e41-e42.
    PubMed     Text format    


    Eur Rev Med Pharmacol Sci

  13. CAO HL, Liu ZJ, Huang PL, Yue YL, et al
    lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206.
    Eur Rev Med Pharmacol Sci. 2019;23:1012-1021.
    PubMed     Text format     Abstract available

  14. LI J, Wang AS, Wang S, Wang CY, et al
    LncSNHG14 promotes the development and progression of bladder cancer by targeting miRNA-150-5p.
    Eur Rev Med Pharmacol Sci. 2019;23:1022-1029.
    PubMed     Text format     Abstract available


    Eur Urol

  15. KAMAT AM, Li R, O'Donnell MA, Black PC, et al
    Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We There Yet? A Systematic Review.
    Eur Urol. 2018;73:738-748.
    PubMed     Text format     Abstract available


    Eur Urol Focus

  16. PEDERSEN M, Stafoggia M, Weinmayr G, Andersen ZJ, et al
    Is There an Association Between Ambient Air Pollution and Bladder Cancer Incidence? Analysis of 15 European Cohorts.
    Eur Urol Focus. 2018;4:113-120.
    PubMed     Text format     Abstract available


    Expert Rev Proteomics

  17. AMARA CS, Vantaku V, Lotan Y, Putluri N, et al
    Recent advances in the metabolomic study of bladder cancer.
    Expert Rev Proteomics. 2019 Feb 16. doi: 10.1080/14789450.2019.1583105.
    PubMed     Text format     Abstract available


    Int Braz J Urol

  18. RACIOPPI M, Di Gianfrancesco L, Ragonese M, Palermo G, et al
    Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
    Int Braz J Urol. 2018;45.
    PubMed     Text format     Abstract available


    J Cell Physiol

  19. SHADPOUR P, Zamani M, Aghaalikhani N, Rashtchizadeh N, et al
    Inflammatory cytokines in bladder cancer.
    J Cell Physiol. 2019 Feb 18. doi: 10.1002/jcp.28252.
    PubMed     Text format     Abstract available

  20. HU J, Zhou L, Song Z, Xiong M, et al
    The identification of new biomarkers for bladder cancer: A study based on TCGA and GEO datasets.
    J Cell Physiol. 2019 Feb 18. doi: 10.1002/jcp.28208.
    PubMed     Text format     Abstract available

  21. YU H, Wang S, Zhu H, Rao D, et al
    LncRNA MT1JP functions as a tumor suppressor via regulating miR-214-3p expression in bladder cancer.
    J Cell Physiol. 2019 Feb 20. doi: 10.1002/jcp.28274.
    PubMed     Text format     Abstract available


    J Exp Clin Cancer Res

  22. MORRA F, Merolla F, Criscuolo D, Insabato L, et al
    CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
    J Exp Clin Cancer Res. 2019;38:90.
    PubMed     Text format     Abstract available

  23. CRISCUOLO D, Morra F, Giannella R, Visconti R, et al
    New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.
    J Exp Clin Cancer Res. 2019;38:91.
    PubMed     Text format     Abstract available


    J Gastrointest Oncol

  24. KUMAR S, Bhoriwal S, Muduly D, Kar M, et al
    Multimodality management of incidentally detected gall bladder cancer: long term results from a tertiary care cancer centre.
    J Gastrointest Oncol. 2019;10:128-133.
    PubMed     Text format     Abstract available


    J Med Chem

  25. CHERUKU RR, Cacaccio J, Durrani F, Tabaczynski WA, et al
    Epidermal Growth Factor Receptor Targeted Multifunctional Photosensitizers for Bladder Cancer Imaging and Photodynamic Therapy.
    J Med Chem. 2019 Feb 18. doi: 10.1021/acs.jmedchem.8b01927.
    PubMed     Text format     Abstract available


    J Urol

  26. KIMURA S, Mari A, Foerster B, Abufaraj M, et al
    Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis.
    J Urol. 2019;201:46-53.
    PubMed     Text format     Abstract available


    Med Sci Monit

  27. TAN Y, Zhang T, Zhou L, Liu S, et al
    MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes.
    Med Sci Monit. 2019;25:1323-1335.
    PubMed     Text format     Abstract available


    Mol Cancer Ther

  28. KALLIFATIDIS G, Smith DK, Morera DS, Gao J, et al
    beta-Arrestins regulate stem cell-like phenotype and response to chemotherapy in bladder cancer.
    Mol Cancer Ther. 2019 Feb 20. pii: 1535-7163.MCT-18-1167.
    PubMed     Text format     Abstract available


    Neoplasma

  29. XU X, You K, Wu B
    Zonula occludens-1 associated nucleic acid binding protein plays an invasion-promoting role in bladder cancer.
    Neoplasma. 2019 Feb 14. pii: 180725N530. doi: 10.4149/neo_2018_180725.
    PubMed     Text format     Abstract available


    Oncogene

  30. ROUDNICKY F, Yoon SY, Poghosyan S, Schwager S, et al
    Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels.
    Oncogene. 2018;37:2573-2585.
    PubMed     Text format     Abstract available


    Oncotarget

  31. LI S, Zhu Y, Liang Z, Wang X, et al
    Correction: Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer.
    Oncotarget. 2019;10:684.
    PubMed     Text format     Abstract available


    PLoS One

  32. HASNAIN Z, Mason J, Gill K, Miranda G, et al
    Machine learning models for predicting post-cystectomy recurrence and survival in bladder cancer patients.
    PLoS One. 2019;14:e0210976.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  33. MULLENDERS J, de Jongh E, Brousali A, Roosen M, et al
    Mouse and human urothelial cancer organoids: A tool for bladder cancer research.
    Proc Natl Acad Sci U S A. 2019 Feb 20. pii: 1803595116.
    PubMed     Text format     Abstract available


    Prog Urol

  34. BALDINI A, Fassi Fehri H, Cerantola Y, Bayle F, et al
    [Do initial experience with an enhanced recovery program after surgery (ERAS) improve postoperative outcomes after cystectomy?]
    Prog Urol. 2018;28:351-358.
    PubMed     Text format     Abstract available


    Scand J Urol

  35. HEMDAN T, Turker P, Malmstrom PU, Segersten U, et al
    Choline-phosphate cytidylyltransferase-alpha as a possible predictor of survival and response to cisplatin neoadjuvant chemotherapy in urothelial cancer of the bladder.
    Scand J Urol. 2018;52:200-205.
    PubMed     Text format     Abstract available

  36. HERMANN GG, Mogensen K, Rosthoj S
    Outpatient diode laser treatment of intermediate-risk non-invasive bladder tumors without sedation: efficacy, safety and economic analysis.
    Scand J Urol. 2018;52:194-198.
    PubMed     Text format     Abstract available


    Urol Ann

  37. KARATZAS A, Tzortzis V
    Lower urinary tract symptoms and bladder cancer in children: The hidden scenario.
    Urol Ann. 2019;11:102-104.
    PubMed     Text format     Abstract available


    World J Urol

  38. KRAJEWSKI W, Rodriguez Faba O, Poletajew S, Palou J, et al
    New predictive nomograms for non-muscle-invasive bladder cancer: it is all about the details.
    World J Urol. 2019 Feb 18. pii: 10.1007/s00345-019-02680.
    PubMed     Text format    

  39. SORIA F, Pisano F, Gontero P, Palou J, et al
    Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.
    World J Urol. 2018;36:1775-1781.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: